2022 Precision Oncology Summit: Personalizing Treatment to Improve Patient Outcomes- Webcast

This accredited continuing education activity “Webcast 2022 Precision Oncology Summit: Personalizing Treatment to Improve Patient Outcomes”, is recorded from the live webinar held on 10/07/2022- 10/08/22. 

If you participated in the live course titled - 2022 Precision Oncology Summit: Personalizing Treatment to Improve Patient Outcomes on 10/07/2022 - 10/08/22 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This is a recorded content from that course on 10/07/2022 - 10/08/22.  However, you may enroll in this activity to review the contents. 

The recorded lectures and subsequent discussions feature leading experts sharing the latest scientific findings and practice-changing advances in precision oncology.

The 2022 Precision Oncology Summit: Personalizing Treatment to Improve Patient Outcomes is an oncology conference featuring leading experts in the field of precision oncology who will provide a comprehensive overview of implications of actionable molecular alterations across common malignancies.

Expert faculty will discuss and analyze the latest scientific findings and practice-changing advances in precision oncology, including the key abstracts relevant to precision oncology presented at the 2022 ASCO Annual Meeting in June 2022.

 

REGISTRATION FEES:

This activity is $0 for all.

Target Audience

  • Hematologists/Oncologists
  • Oncology Nurse Practitioners
  • Oncology Pharmacists
  • Oncology Physician Assistants
  • Oncology Fellows/Residents
  • Oncology Nurses
  • Researchers and others involved in the care of cancer patients

Learning Objectives

Upon successful completion of this educational activity on precision oncology, participants will be able to:

  1. Identify frequent molecular abnormalities across several common malignancies and understand appropriate timing of testing to detect these abnormalities.
  2. Interpret results of next generation sequencing and other biomarkers predictive of response to targeted therapies and recognize the challenges involved.
  3. Explain the role, including advantages and disadvantages, of different testing methodologies available for selection of targeted therapies.
  4. Plan optimal molecular-targeted treatment strategies for treatment of cancer.
  5. Outline emerging research, the mechanism of action, and the role of novel molecular-targeted therapies in clinical investigation for cancer patients.
Course summary
Available credit: 
  • 6.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.50 Contact Hours.
Course opens: 
10/07/2022
Course expires: 
10/07/2023
Cost:
$0.00

Session 1: Methods in Precision Oncology 

20 minutes-   Next generation sequencing for identification of molecular targets - James Ford, MD

15 minutes-  Beyond sequencing – methods in identifying tumor biomarkers for targeted therapies - Vivek Subbiah, MD

20 minutes- Germline genetic testing for cancer prevention and treatment - Siddhartha Yadav, MD

15 minutes- Clinical utility of circulating tumor DNA in cancer treatment - Manish Kohli, MD

5 minutes-  Q and A/Panel discussion - Christos Vaklavas, MD, James Ford, MD, Vivek Subbiah, MD, Siddhartha Yadav, MD, and Manish Kohli, MD

 

Session 2: Somatic and germ line testing: real world challenges 

15 minutes: Challenges and solutions with somatic genetic testing: what is needed - Beverly Chigarira, MS

15 minutes: Challenges and solutions with germline testing - Kristen Pauley, MS, GCG

 

Session 3: Precision oncology in breast and ovarian cancer

20 minutes: Precision oncology in metastatic breast cancer - Mark Pegram, MD

15 minutes: Non-metastatic breast cancer - Christos Vaklavas, MD

15 minutes: Key concepts on precision in gynecological malignancies - Theresa Werner, MD

 

Session 4: Precision Oncology in Lung Cancer

20 minutes: Metastatic lung cancer - Katie Kerrigan, DO     

15 minutes: Adjuvant treatment of lung cancer - Aaron Mansfield, MD

20 minutes: Panel discussion - Joseph Rosales, MD, Katie Kerrigan, DO, and Aaron Mansfield, MD

 

 Session 5: Precision Oncology in GI Malignancies

 20 minutes: Precision Oncology in Colon cancer - Stacey Cohen, MD

 15 minutes: Hepatobiliary and pancreatic malignancies - Chris Nevala-Plagemann, MD

 

Session 6: Precision oncology in prostate cancer

15 minutes: Precision oncology in metastatic prostate cancer - Benjamin Maughan, MD

20 minutes: Precision oncology in metastatic bladder cancer - Sumati Gupta, MD

 

Session 7: Precision oncology in hematological malignancies

20 minutes:  Precision oncology in acute leukemias - Tibor Kovacsovics, MD

15 minutes: Precision oncology in multiple myeloma - Douglas Sborov, MD, MS

 

Session 8: Precision medicine: perspectives from molecular pathologists

15 minutes: Pre-Analytical Variables and Precision Oncology: How we can improve our Patient Management - Deepika Sirohi, MD

20 minutes: Critical Role of Molecular Pathologist in Precision Oncology - Allie Grossmann, MD, PhD

 

Session 9: Implementation science in precision oncology

20 minutes: Disparities in precision oncology and improving access to evidence-based testing for targeted therapies - Jack West, MD

15 minutes: Strategies for clinical implementation of precision oncology - Howard L. McLeod, Pharm.D., FASCO, FCCP

 

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Manish Kohli, MD has a financial relationship (Consulting) with Tempus.

Srinivas Tantravahi, MD has a financial relationship (Consulting) with Novartis; a financial relationship (Consulting) with AbbVie; a financial relationship (Research support/Grant
Consultant) with Karyopharm Therapeutics.

COMMITTEE MEMBER(S)

Daniel Isaac  has no relevant financial relationships to disclose at this time.

COURSE DIRECTOR(S)

Neeraj Agarwal, MD has a financial relationship (Other) with Aveo, Bayer, Bristol Myers Squibb, Calithera, Eli Lilly, Exelixis, Genentech, Gilead, Merck, MEI Pharma, .

Theresa Werner, MD has a financial relationship (Other) with Mersana Therapeutics.

MODERATOR(S)

Daniel Isaac has no relevant financial relationships to disclose at this time.

Joseph Rosales, MD has no relevant financial relationships to disclose at this time.

Paolo Tarantino, MD has a financial relationship (Professional Services) with AstraZeneca.

David Zhen, MD has a financial relationship (Grant Or Contract) with Daiichi-Sankyo; financial relationship (Grant Or Contract) with SeaGen; financial relationship (Grant Or Contract) with Merck; financial relationship (Grant Or Contract) with Astra Zeneca.

SPEAKER(S)

Neeraj Agarwal, MD has a financial relationship (Other) with Aveo, Bayer, Bristol Myers Squibb, Calithera, Eli Lilly, Exelixis, Genentech, Gilead, Merck, MEI Pharma, .

Beverly Chigarira has no relevant financial relationships to disclose at this time.

Stacey Cohen has a financial relationship (Independent contractor) with Delcath; financial relationship (Independent contractor) with Proventus - Isofol; financial relationship (Independent contractor) with Kallyope; financial relationship (Independent contractor) with Bayer; financial relationship (Independent contractor) with Taiho; financial relationship (Independent contractor) with Pfizer.

James Ford, MD, FASCO has no relevant financial relationships to disclose at this time.

Allie Grossmann, MD PhD has a financial relationship (Employment) with Merck.

Sumati Gupta, MD has a financial relationship (Grant Or Contract) with Clovis; financial relationship (Grant Or Contract) with Astellas; financial relationship (Grant Or Contract) with QED; financial relationship (Grant Or Contract) with Novartis; financial relationship (Grant Or Contract) with Seattle Genetics; financial relationship (Grant Or Contract) with Rexahn; financial relationship (Grant Or Contract) with Astra Zeneca; financial relationship (Grant Or Contract) with Pfizer; financial relationship (Grant Or Contract) with Incyte; financial relationship (Grant Or Contract) with Acrotech; financial relationship (Grant Or Contract) with Merck; financial relationship (Stock Options) with Salarius; financial relationship (Grant Or Contract) with Bristol Myers Squibb; financial relationship (Grant Or Contract) with LSK.

Katie Kerrigan, DO has no relevant financial relationships to disclose at this time.

JongTaek Kim, MD, MS has no relevant financial relationships to disclose at this time.

Jennifer Lloyd has no relevant financial relationships to disclose at this time.

Aaron Mansfield, M.D. has a financial relationship (Professional Services) with University of Miami Int'l Mesothelioma Symposium; financial relationship (Professional Services) with BMS; financial relationship (Professional Services) with Chugai Pharmaceutical Co Ltd (Roche); financial relationship (Professional Services) with Miami Mesothelioma Symposium; financial relationship (Professional Services) with Antoni van Leeuwenhoek Kanker Instituut; financial relationship (Professional Services) with AstraZeneca; financial relationship (Professional Services) with Johnson & Johnson Global Services; financial relationship (Professional Services) with Ideology Health LLC; financial relationship (Professional Services) with Answers in CME; financial relationship (Professional Services) with AbbVie; financial relationship (Professional Services) with Janssen; financial relationship (Professional Services) with TRIPTYCH Health Partners; financial relationship (Professional Services) with Intellisphere; financial relationship (Other) with Mesothelioma Applied Research Foundation; financial relationship (Travel) with Roche; financial relationship (Professional Services) with Genentech; financial relationship (Professional Services) with Rising Tide.

Anna Matynia  has no relevant financial relationships to disclose at this time.

Benjamin Maughan, M.D., PharmD has a financial relationship (Independent contractor) with Janssen; financial relationship (Independent contractor) with Tempus; financial relationship (Independent contractor) with Peloton Therapeutis; financial relationship (Independent contractor) with Clovis; financial relationship (Independent contractor) with Bayer Oncology; financial relationship (Independent contractor) with AVEO Oncology; financial relationship (Independent contractor) with Bristol-Myers Squibb; financial relationship (Independent contractor) with Exelixis; financial relationship (Independent contractor) with Pfizer; financial relationship (Independent contractor) with Astellas; financial relationship (Independent contractor) with Merck; financial relationship (Independent contractor) with Abbvie.

Howard McLeod has a financial relationship (Stock Options) with Vyant Bio; financial relationship (Stock) with Genovation; financial relationship (Independent contractor) with Viecure; financial relationship (Stock) with Clarified Precision Medicine.

Christopher Nevala-Plagemann, MD, MSCI has no relevant financial relationships to disclose at this time.

Afaf Osman has a financial relationship (Grant Or Contract) with Kayopharm Therapeutics ;financial relationship (Grant Or Contract) with Syros Pharmaceuticals.

Ami Patel  has a financial relationship (Grant Or Contract) with Genentech Roche.

Sagar Patel, MD has a financial relationship (Grant Or Contract) with CareDx; financial relationship (Grant Or Contract) with Kite Pharma;financial relationship (Grant Or Contract) with Medexus.

Kristen Pauley, MS, LCGC has no relevant financial relationships to disclose at this time.

Mark Pegram, MD has no relevant financial relationships to disclose at this time.

Douglas Sborov, MD MS has a financial relationship (Professional Services) with Abbvie; financial relationship (Professional Services) with GlaxoSmithKline; financial relationship (Professional Services) with Janssen; financial relationship (Professional Services) with Celgene; financial relationship (Professional Services) with Sanofi.

Deepika Sirohi, MD has no relevant financial relationships to disclose at this time.

Vivek Subbiah, MD has a financial relationship (Grant Or Contract) with Novartis; financial relationship (Grant Or Contract) with Blueprint Medicines; financial relationship (Grant Or Contract) with Amgen; financial relationship (Grant Or Contract) with LOXO/ Eli Lilly; financial relationship (Grant Or Contract) with Bayer; financial relationship (Grant Or Contract) with Relay Therapeutics.

Umang Swami, MD, MS has a financial relationship (Other) with Seattle Genetics; financial relationship (Other) with Exelixis; financial relationship (Other) with Astellas.

Soffe Timm, BSN RN has no relevant financial relationships to disclose at this time.

Christos Vaklavas, M.D., Associate Professor has no relevant financial relationships to disclose at this time.

Theresa Werner, MD has a financial relationship (Other) with Mersana Therapeutics.

Howard (Jack) West, MD, Associate Professor, City of Hope Cancer Center, Los Angeles, CA has a financial relationship (Independent contractor) with Merck; financial relationship (Independent contractor) with Genentech/Roche; financial relationship (Independent contractor) with Takeda; financial relationship (Independent contractor) with AstraZeneca; financial relationship (Independent contractor) with Regeneron; financial relationship (Independent contractor) with Mirati.

Siddhartha Yadav, Siddhartha Yadav, MD, FACP has no relevant financial relationships to disclose at this time.

Important Information about Claiming CME for this activity:

If you participated in the live course titled - 2022 Precision Oncology Summit: Personalizing Treatment to Improve Patient Outcomes on 10/07/2022 - 10/08/22 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This is a recorded content from that course on 10/07/2022 - 10/08/22. 

The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians.

The Binaytara Foundation designates this enduring activity for a maximum of 6.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity meets the criteria for up to 6.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.

Nursing Contact Hours: Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.50 Contact Hours.

ABSM Maintenance of Certificate Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.50 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Available Credit

  • 6.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.50 Contact Hours.

Price

Cost:
$0.00
Please login or register to take this course.

REGISTRATION FEES:

This activity is $0 for all.

Cancellation Policy

You may cancel your enrollment at any time. No credits will be offered if you do not complete all required steps of this activity which include registration, watching the recorded content, and completion of pre & post tests as well as course evaluations